Drug Pricing Value Assessment Methods in the United States: The National Pharmaceutical Council Viewpoint
April Rieger2023-11-15T19:03:48-05:00August 17th, 2015|Categories: Blog, HEOR Feature|Tags: drug pricing, ETAP, ICER, Institute for Clinical and Economic Review, National Pharmaceutical Council, NPC, Robert Dubois, tHEORetically Speaking, Value Benchmarks|
Swarali Tadwalkar, MPHIntern Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
HEOR
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Press Release
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication